ITRMF — Iterum Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Iterum Therapeutics To Report Second Quarter 2023 Financial Results On August 11, 2023
Brief: Iterum Therapeutics Reports Q1 2023 Financial Results
Brief: Iterum Therapeutics Reports Fourth Quarter Results
Iterum gains on U.S. patent office clearance for antibiotic combination therapy
Brief: Iterum Therapeutics Announces Issuance Of Allowance For U.S. Patent Covering Oral Sulopenem
Brief: Iterum Therapeutics Reports Q3 2022 Results
Iterum Therapeutics PLC expected to post a loss of $1.05 a share - Earnings Preview
Brief: Iterum Announces Beginning Of Dosing In Phase 3 Trial Of Oral Sulopenem In Uncomplicated Urinary Tract Infections
Brief: Iterum Therapeutics PLC Files For Mixed Shelf Of Up To $100 Million
Brief: Iterum Therapeutics Announces Issuance Of Allowance For U.S. Patent Covering Oral Sulopenem
Brief: Iterum Therapeutics Regains Compliance With Nasdaq Bid Price Rule
U.S. STOCKS ON THE MOVE-Manchester United, Endo International, Blue Apron, Bed Bath & Beyond
U.S. STOCKS ON THE MOVE-Take-Two, RedHill Biopharma, Gold Miners,
U.S. STOCKS ON THE MOVE-Target, Bed Bath & Beyond, Hill International, Low's
Iterum drops on 1-for-15 reverse share split plan
Brief: Iterum Therapeutics reports Q2 results
U.S. STOCKS ON THE MOVE-Iterum Therapeutics PLC, Titan Machinery Inc, Volcon Inc
Iterum rises after FDA agrees on design for UTI drug trial
Brief: Iterum Therapeutics Announces Special Protocol Assessment Agreement With FDA